Labshake search

1 - 10 of 10 citations for Human Immunodeficiency Virus Tat Protein HIV 1 Clade B BH10 since 2019

• Novel mRNA-based VP8* vaccines against rotavirus are highly immunogenic in rodents

  Sandro Roier, et al., bioRxiv - Immunology 2023

  Quote: ... The protein vaccines were alum-adjuvanted by adsorption of the recombinant fusion proteins to aluminum hydroxide (Alhydrogel®; Croda, Frederikssund, Denmark) as previously described22 ...
• A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infection

  Lorena M. Coria, et al., bioRxiv - Immunology 2021

  Quote: ... RBD and U-Omp19 proteins were adsorbed to Alhydrogel® (CRODA, Inc.). Protein adsorption was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis ...
• Safety and Immunogenicity Evaluation of Inactivated whole-virus-SARS-COV-2 As Emerging Vaccine Development In Egypt

  Amani A. Saleh, et al., bioRxiv - Immunology 2021

  Quote: ... or 100 μg total protein with aluminium hydroxide (Alhydrogel® CRODA health care Corp.) as adjuvant (0·45 mg/mL ...
• Metabolic adaptation to progressive mitochondrial dysfunction in aging POLG^D257A mice

  Esther W. Lim, et al., bioRxiv - Biochemistry 2021

  Quote: ... were extracted from 10 µL of plasma with 750 µL of ice cold 1:1 methanol/water solution and 500 µL of ice cold chloroform with inclusion of EquiSLASH (Avanti, Croda International Plc, 330731), C15 Glucosyl(β ...
• Metabolic adaptation to progressive mitochondrial dysfunction in aging POLG^D257A mice

  Esther W. Lim, et al., bioRxiv - Biochemistry 2021

  Quote: ... C15 Glucosyl(β) Ceramide-d7 (d18:1-d7/15:0) (Avanti, Croda International Plc, 330729), and C15 Lactosyl(β ...
• Metabolic adaptation to progressive mitochondrial dysfunction in aging POLG^D257A mice

  Esther W. Lim, et al., bioRxiv - Biochemistry 2021

  Quote: ... and C15 Lactosyl(β) Ceramide-d7 (d18:1-d7/15:0) (Avanti, Croda International Plc, 330727) as internal standards ...
• Metabolic adaptation to progressive mitochondrial dysfunction in aging POLG^D257A mice

  Esther W. Lim, et al., bioRxiv - Biochemistry 2021

  Quote: ... 200 picomoles of C15 ceramide-d7 (d18:1-d7/15:0) (Avanti, Croda International Plc, 860681), 100 picomoles of C13-dihydroceramide-d7 (d18:0-d7/13:0 ...
• 1-deoxysphingolipid biosynthesis compromises anchorage-independent growth and plasma membrane endocytosis in cancer cells

  Thekla Cordes, et al., bioRxiv - Cancer Biology 2022

  Quote: ... 200 picomoles of C15 ceramide-d7 (d18:1-d7/15:0) (Avanti, Croda International Plc, 860681), 100 picomoles of C13-dihydroceramide-d7 (d18:0-d7/13:0 ...
• Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidate

  Danmei Su, et al., bioRxiv - Immunology 2021

  Quote: ... All animals in Stage 1 received a priming dose (Dose 1) adjuvanted with 10 µg CpG 1018 (Dynavax) plus 75 µg Alum (aluminum hydroxide, Croda), whereas half of the animals in each group received a boost (Dose 2 ...
• Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection

  Lei Li, et al., bioRxiv - Immunology 2021

  Quote: ... with 1 or 5 μg rSp alone or mixed with either 1 mg Advax-SM adjuvant or where indicated 50 μg Al(OH)3 (2% Alhydrogel, Croda Denmark) in the thigh muscle at weeks 0 and 2 ...